María Parrilla Vallejo
A5035517433- Glaucoma and retinal disorders
- Retinal Diseases and Treatments
- Ocular Surface and Contact Lens
- Neurological Disorders and Treatments
- Corneal surgery and disorders
Hospital Universitario Virgen Macarena
2024
A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety a topical preservative-free tafluprost (0.0015%) timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) ocular hypertension (OHT) demonstrating insufficient response to beta-receptor blockers or prostaglandin analogue (PGA) monotherapy. Mean intraocular pressure (IOP) change from baseline was measured at study visits following...
Purpose: Data are presented from ophthalmology clinics in Spain participating the VISIONARY study, examining effectiveness, tolerability, and safety of preservative-free tafluprost (0.0015%) timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) treatment OAG OHT. Methods: An observational, multicenter prospective study examined outcomes following a switch to PF FC adult OAG/OHT patients demonstrating insufficient response beta-blocker or prostaglandin analog (PGA) monotherapy....
The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-optimally controlled topical prostaglandin analogue (PGA) beta-blocker monotherapy. Current subanalyses have examined these data according to baseline A European, prospective, observational included adults (aged...
Purpose Metaplasia, chronic inflammation and subconjunctival fibrosis favor failure of bleb-dependent glaucoma surgery. The aim the study is to identify patients at a higher risk post-surgical failure.